Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arcoxia Safety Can Be Addressed In Labeling, Merck Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck is working with international regulatory agencies on appropriate labeling changes to reflect cardiovascular safety issues that prompted withdrawal of Vioxx. Arcoxia's cardiovascular safety profile is strong for "short-term use," Merck says.

You may also be interested in...



Merck’s Arcoxia “Approvable” At FDA

The agency is seeking additional safety and efficacy data for the COX-2 inhibitor, the company says. Merck is working with international regulatory agencies on labeling changes for Arcoxia to address safety issues prompted by the Vioxx withdrawal.

Merck’s Arcoxia “Approvable” At FDA

The agency is seeking additional safety and efficacy data for the COX-2 inhibitor, the company says. Merck is working with international regulatory agencies on labeling changes for Arcoxia to address safety issues prompted by the Vioxx withdrawal.

Merck Gives Earnings Update Oct. 21, Pfizer Oct. 20

Impact of Merck’s Vioxx withdrawal is likely to surface during both companies’ presentations; Merck will present data on Vioxx 25 mg at a rheumatology conference earlier in the week.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel